A Phase 1 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer

Trial Profile

A Phase 1 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs SRA 737 (Primary) ; Cisplatin; Gemcitabine
  • Indications Bladder cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Sierra Oncology
  • Most Recent Events

    • 02 Jun 2017 Trial design of the study, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 24 May 2017 According to a Sierra Oncology media release, data from this trial will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
    • 10 May 2017 According to a Sierra Oncology media release, stage 1 of this study (SRA737+ gemcitabine and cisplatin) has concluded enrollment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top